Greenleaf Trust Sells 604 Shares of Becton, Dickinson and Company (NYSE:BDX)

Greenleaf Trust lessened its position in Becton, Dickinson and Company (NYSE:BDX) by 13.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,050 shares of the medical instruments supplier’s stock after selling 604 shares during the quarter. Greenleaf Trust’s holdings in Becton, Dickinson and Company were worth $976,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in BDX. Kingswood Wealth Advisors LLC bought a new stake in shares of Becton, Dickinson and Company in the 1st quarter worth about $229,000. Brookstone Capital Management lifted its holdings in shares of Becton, Dickinson and Company by 1.2% in the 1st quarter. Brookstone Capital Management now owns 11,725 shares of the medical instruments supplier’s stock worth $2,901,000 after acquiring an additional 139 shares during the last quarter. Fifth Third Wealth Advisors LLC bought a new stake in shares of Becton, Dickinson and Company in the 1st quarter worth about $542,000. Indiana Trust & Investment Management CO lifted its holdings in shares of Becton, Dickinson and Company by 126.9% in the 1st quarter. Indiana Trust & Investment Management CO now owns 236 shares of the medical instruments supplier’s stock worth $58,000 after acquiring an additional 132 shares during the last quarter. Finally, Capital Asset Advisory Services LLC lifted its holdings in Becton, Dickinson and Company by 45.2% during the 1st quarter. Capital Asset Advisory Services LLC now owns 1,484 shares of the medical instruments supplier’s stock valued at $365,000 after buying an additional 462 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.8 %

NYSE BDX opened at $238.62 on Friday. The company’s 50-day simple moving average is $237.33 and its two-hundred day simple moving average is $235.16. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.36 and a current ratio of 1.85. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $262.23. The company has a market capitalization of $68.96 billion, a price-to-earnings ratio of 52.56, a price-to-earnings-growth ratio of 1.79 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The firm had revenue of $4.99 billion for the quarter, compared to the consensus estimate of $5.08 billion. During the same quarter in the previous year, the firm earned $2.96 EPS. The company’s quarterly revenue was up 2.3% compared to the same quarter last year. Equities analysts forecast that Becton, Dickinson and Company will post 13.11 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on BDX. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. Stifel Nicolaus lifted their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a report on Friday, July 26th. Raymond James decreased their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Finally, Evercore ISI raised their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Buy” and a consensus price target of $282.63.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.